Related Experiment Videos
Impact of antimigraine compounds on cognitive processing: a placebo-controlled crossover study
Stefan Evers1, Jutta Rüschenschmidt, Achim Frese
1Department of Neurology, University of Münster, Germany.
Headache
|November 25, 2003
Summary
Acute antimigraine drugs like ergotamine tartrate and zolmitriptan may cause mild, short-term cognitive impairment. Sumatriptan and placebo showed no significant cognitive effects in healthy subjects.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Migraine treatments aim to alleviate pain without causing adverse cognitive effects.
- Understanding the short-term cognitive impact of acute antimigraine medications is crucial for patient safety.
Purpose of the Study:
- To assess the potential for acute cognitive impairment following the administration of common antimigraine drugs.
- Investigate the short-term effects of sumatriptan, zolmitriptan, and ergotamine tartrate on cognitive processing.
Main Methods:
- A placebo-controlled, double-blind, crossover study involving 16 healthy participants.
- Cognitive function was evaluated using event-related potentials and the d2 test before and 2 hours after drug intake.
- Participants received placebo, sumatriptan (100 mg), zolmitriptan (2.5 mg), or ergotamine tartrate (2 mg) in a randomized order.
Main Results:
- Ergotamine tartrate significantly increased N2 latency in event-related potentials.
- The d2 test showed improved performance with placebo and sumatriptan, but no significant change with zolmitriptan or ergotamine.
- No significant changes were observed in other event-related potential parameters or in the number of errors and concentration on the d2 test.
Conclusions:
- Ergotamine tartrate and, to a lesser extent, zolmitriptan may induce mild, transient cognitive alterations.
- Sumatriptan did not demonstrate any significant short-term cognitive impact.
- Observed cognitive changes were minimal and unlikely to be clinically significant.